NASDAQ : LIMN
Liminatus Pharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 3.07M | 2.97M | 644.62K | 1.06M | 856.00K | 197.00K |
| Research & Development | 1.00M | 2.69M | 3.76M | 1.85M | 3.80M | |
| Operating Expenses | 4.07M | 2.97M | 3.33M | 4.82M | 2.71M | 4.00M |
| Operating Income | -4.07M | -2.97M | -3.33M | -4.82M | -2.71M | -4.00M |
| Interest Expense | -75.58K | -215.90K | -338.88K | -175.00K | -219.00K | -1.61M |
| Interest & Investment Income | 8.22K | 76.59K | 122.53K | 10.00K | ||
| Other Non Operating Income (Expenses) | -1.80M | -1.88M | ||||
| EBT Excluding Unusual Items | -5.93M | -4.99M | -3.55M | -4.98M | -2.93M | -5.61M |
| Other Unusual Items | -6.59M | -5.22M | ||||
| Pretax Income | -12.52M | -10.21M | -3.55M | -4.98M | -2.93M | -5.61M |
| Net Income | -12.52M | -10.21M | -3.55M | -4.98M | -2.93M | -5.61M |
| Net Income to Common | -12.52M | -10.21M | -3.55M | -4.98M | -2.93M | -5.61M |
| Shares Outstanding (Basic) | 693.40K | 475.07K | 350.00K | 2.05M | 711.13K | |
| Shares Outstanding (Diluted) | 693.40K | 475.07K | 350.00K | 2.05M | 711.13K | |
| EPS (Basic) | -18.06 | -21.48 | -10.13 | -2.43 | -4.12 | |
| EPS (Diluted) | -18.06 | -21.48 | -10.13 | -2.43 | -4.12 | |
| Free Cash Flow | -3.99M | -9.98M | -1.45M | -3.35M | -869.00K | -168.00K |
| Free Cash Flow Per Share | -5.75 | -21.00 | -4.15 | -1.63 | -1.22 | |
| EBITDA | -4.06M | -2.97M | -2.71M | -4.00M | ||
| D&A For EBITDA | 2.07K | 1.83K | 1.00K | 1.00K | ||
| EBIT | -4.07M | -2.97M | -3.33M | -4.82M | -2.71M | -4.00M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.02M | 337.65K | 56.32K | 434.00K | 5.05M | |
| Cash & Short-Term Investments | 3.02M | 337.65K | 56.32K | 434.00K | 5.05M | |
| Other Receivables | 126.00K | 100.00K | 54.00K | |||
| Receivables | 3.67M | 945.00K | 100.00K | 54.00K | ||
| Prepaid Expenses | 375.37K | 162.92K | 155.50K | 22.00K | 10.00K | |
| Other Current Assets | 1.40M | 840.00K | 1.68M | 2.64M | ||
| Total Current Assets | 3.39M | 500.57K | 5.28M | 2.24M | 6.84M | 2.69M |
| Property, Plant & Equipment | 11.23K | 12.22K | 941.00 | 1.00K | 1.00K | 1.00K |
| Other Long-Term Assets | 126.28K | |||||
| Total Assets | 3.40M | 512.79K | 5.41M | 2.24M | 6.84M | 2.69M |
| Accounts Payable | 655.09K | 582.23K | 1.48M | 933.00K | 508.00K | 419.00K |
| Accrued Expenses | 241.40K | 203.92K | 3.10M | 858.00K | 441.00K | 332.00K |
| Short-Term Debt | 1.44M | 1.44M | 19.97M | 16.05M | 16.50M | 13.18M |
| Other Current Liabilities | 701.43K | 8.07M | 195.25K | 195.00K | 204.00K | 140.00K |
| Total Current Liabilities | 3.04M | 10.30M | 24.75M | 18.04M | 17.65M | 14.07M |
| Other Long-Term Liabilities | 62.67K | 29.24K | ||||
| Total Liabilities | 3.10M | 10.33M | 24.75M | 18.04M | 17.65M | 14.07M |
| Common Stock | 5.60K | 2.71K | 1.75K | 4.71M | 4.17M | 267.00K |
| Additional Paid-In Capital | 41.70M | 29.05M | 9.32M | 4.61M | 5.16M | 5.56M |
| Retained Earnings | -41.40M | -38.87M | -28.67M | -25.12M | -20.14M | -17.21M |
| Shareholders' Equity | 300.61K | -9.81M | -19.34M | -15.79M | -10.81M | -11.38M |
| Total Liabilities & Equity | 3.40M | 512.79K | 5.41M | 2.24M | 6.84M | 2.69M |
| Total Debt | 1.44M | 1.44M | 19.97M | 16.05M | 16.50M | 13.18M |
| Net Cash (Debt) | 1.57M | -1.10M | -19.92M | -15.62M | -11.45M | -13.18M |
| Net Cash Per Share | 2.27 | -2.33 | -56.90 | -7.62 | -16.10 | |
| Filing Date Shares Outstanding | 1.34M | 897.55K | 112.22M | 112.22M | 73.67M | |
| Total Common Shares Outstanding | 1.12M | 541.29K | 112.22M | 112.22M | 73.67M | |
| Working Capital | 352.04K | -9.80M | -19.47M | -15.79M | -10.81M | -11.38M |
| Book Value Per Share | 0.27 | -18.13 | -0.17 | -0.14 | -0.15 | |
| Tangible Book Value | 300.61K | -9.81M | -19.34M | -15.79M | -10.81M | -11.38M |
| Tangible Book Value Per Share | 0.27 | -18.13 | -0.17 | -0.14 | -0.15 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -12.52M | -10.21M | -3.55M | -4.98M | -2.93M | -5.61M |
| Depreciation & Amortization | 2.07K | 1.83K | 1.00K | |||
| Asset Writedown & Restructuring Costs | 900.00K | 900.00K | ||||
| Other Operating Activities | 8.52M | 7.23M | 1.50M | |||
| Change in Accounts Payable | -2.29M | -4.04M | -10.75K | 425.00K | 89.00K | 39.00K |
| Change in Other Net Operating Assets | 2.32M | -2.95M | 2.11M | 1.21M | 1.07M | 3.01M |
| Operating Cash Flow | -3.97M | -9.96M | -1.45M | -3.35M | -869.00K | -168.00K |
| Capital Expenditures | -13.11K | -13.11K | ||||
| Investing Cash Flow | -13.11K | -788.11K | -2.85M | -819.00K | ||
| Short-Term Debt Issued | 4.34M | 3.92M | 3.41M | 9.44M | ||
| Total Debt Issued | 4.34M | 3.92M | 3.41M | 9.44M | ||
| Short-Term Debt Repaid | -1.30M | -3.86M | -7.03M | |||
| Total Debt Repaid | -1.30M | -1.30M | -3.86M | -7.03M | ||
| Net Debt Issued (Repaid) | -1.30M | 3.04M | 3.92M | -450.00K | 2.42M | |
| Issuance of Common Stock | 3.80M | 10.56M | 4.20M | |||
| Repurchase of Common Stock | -700.00K | |||||
| Other Financing Activities | 3.16M | -2.56M | ||||
| Financing Cash Flow | 5.66M | 11.03M | 3.92M | -450.00K | 5.92M | |
| Net Cash Flow | 1.68M | 281.34K | -378.07K | -4.61M | 5.05M | -168.00K |
| Free Cash Flow | -3.99M | -9.98M | -1.45M | -3.35M | -869.00K | -168.00K |
| Free Cash Flow Per Share | -5.75 | -21.00 | -4.15 | -1.63 | -1.22 | |
| Levered Free Cash Flow | -10.01M | 7.14M | -2.92M | -2.30M | -671.00K | |
| Unlevered Free Cash Flow | -9.96M | 7.28M | -2.71M | -2.19M | -534.12K | |
| Cash Interest Paid | 503.00K | |||||
| Change in Working Capital | 31.46K | -6.98M | 2.10M | 1.64M | 1.16M | 3.05M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.79M | 16.51M | 80.10M | 75.48M | 349.14M | 337.41M |
| Enterprise Value | 2.21M | 17.23M | 97.32M | 89.29M | ||
| Last Close Price | 2.82 | 30.50 | 561.00 | 516.50 | 506.00 | 489.00 |
| PB Ratio | 10.50 | -1.68 | -4.14 | -4.78 | -32.30 | -29.64 |
| Debt / Equity Ratio | 4.80 | -0.15 | -1.03 | -1.02 | -1.53 | -1.16 |
| Net Debt / Equity Ratio | -5.24 | -0.11 | -1.03 | -0.99 | -1.06 | -1.16 |
| Net Debt / EBITDA Ratio | 0.39 | -0.37 | -4.23 | -3.30 | ||
| Net Debt / FCF Ratio | 0.40 | -0.11 | -13.73 | -4.67 | -13.18 | -78.47 |
| Quick Ratio | 0.99 | 0.03 | 0.00 | 0.03 | 0.29 | 0.00 |
| Current Ratio | 1.12 | 0.05 | 0.21 | 0.12 | 0.39 | 0.19 |
| Return on Assets (ROA) | -95.65% | -62.65% | -54.41% | -66.30% | -35.51% | |
| Return on Capital Employed (ROCE) | -1,119.00% | 30.30% | 17.20% | 30.50% | 25.10% | 35.10% |
| Earnings Yield | -640.45% | -61.82% | -4.43% | -6.60% | -0.84% | -1.66% |
| FCF Yield | -105.23% | -60.43% | -1.81% | -4.43% | -0.25% | -0.05% |
| Buyback Yield / Dilution | -82.95% | -35.73% | 82.93% | -188.25% |